ACE2-angiotensin-(1-7)-Mas axis might be a promising therapeutic target for pulmonary arterial hypertension

Nature Reviews Cardiology

Volumn 12, Issue 6, 2015, Pages p374-

  Dai, Hailong ^a   Jiang, Lihong ^b   Xiao, Zhicheng ^a   Guang, Xuefeng ^a  

^a KUNMING MEDICAL UNIVERSITY   (China)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACE2 ANGIOTENSIN (1 7) MAS RECEPTOR; ANGIOTENSIN; DIPEPTIDYL CARBOXYPEPTIDASE; UNCLASSIFIED DRUG;

CONGENITAL HEART DISEASE; HEART VENTRICLE OVERLOAD; HUMAN; HYPOTENSION; LETTER; LUNG ARTERY PRESSURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SIGNAL TRANSDUCTION; VASODILATATION; HYPERTENSION, PULMONARY;

HUMANS; HYPERTENSION, PULMONARY;

EID: 84929949566     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2015.6-c1     Document Type: Letter

References (14)

1. Latus, H., Delhaas, T., Schranz, D. & Apitz, C. Treatment of pulmonary arterial hypertension in children. Nat. Rev. Cardiol. 12, 244-254 (2015).
2. Kleinsasser, A. et al. Recombinant angiotensin-converting enzyme 2 suppresses pulmonary vasoconstriction in acute hypoxia. Wilderness Environ. Med. 23, 24-30 (2012).
3. Li, G. et al. ACE2 activation confers endothelial protection and attenuates neointimal lesions in prevention of severe pulmonary arterialhypertension in rats. Lung 191, 327-336 (2013).
4. Rondelet, B. et al. Prevention of pulmonary vascular remodeling and of decreased BMPR-2 expression by losartan therapy in shunt-induced pulmonary hypertension. Am. J. Physiol. Heart Circ. Physiol. 289, H2319-H2324 (2005).
5. Shenoy, V. et al. Diminazene attenuates pulmonary hypertension and improves angiogenic progenitor cell functions in experimental models. Am. J. Respir. Crit. Care Med. 187, 648-657 (2013).
6. Ferreira, A. J. et al. Evidence for angiotensin-converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am. J. Respir. Crit. Care Med. 179, 1048-1054 (2009).
7. Li, G. et al. Angiotensin-converting enzyme 2 activation protects against pulmonary arterial hypertension through improving early endothelial function and mediating cytokines levels. Chin. Med. J. 125, 1381-1388 (2012).
8. Yamazato, Y. et al. Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer. Hypertension 54, 365-371 (2009).
9. Shenoy, V. et al. The angiotensin-converting enzyme 2/angiogenesis-(1-7)/Mas axis confers cardiopulmonary protection against lung fibrosis and pulmonary hypertension. Am. J. Respir. Crit. Care Med. 182, 1065-1072 (2010).
10. Dai, H. L. et al. The changes of serum angiotensin-converting enzyme 2 in patients with pulmonary arterial hypertension due to congenital heart disease. Cardiology 124, 208-212 (2013).
11. Dai, H. et al. Decreased levels of serum angiotensin-(1-7) in patients with pulmonary arterial hypertension due to congenital heart disease. Int. J. Cardiol. 176, 1399-1401 (2014).
12. Shenoy, V. et al. Oral delivery of angiotensin-converting enzyme 2 and angiotensin-(1-7) bioencapsulated in plant cells attenuates pulmonary hypertension. Hypertension 64, 1248-1259 (2014).
13. Grobe, J. L. & Sigmund, C. D. Another reason to eat your greens: cardiopulmonary protection by dietary delivery of angiotensin-converting enzyme-2 and angiotensin-(1-7) made in plants. Hypertension 64, 1182-1183 (2014).
14. US National Library of Medicine. ClinicalTrials.gov [online], https://clinicaltrials.gov/ct2/show/NCT01884051 (2014).